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Abstract
Hexanucleotide repeat expansion in C9orf72 is the most common genetic cause of frontotemporal dementia and
amyotrophic lateral sclerosis, but the pathogenic mechanism of this mutation remains unresolved.
Haploinsufficiency has been proposed as one potential mechanism. However, insights if and how reduced C9orf72
proteins levels might contribute to disease pathogenesis are still limited because C9orf72 expression, localization
and functions in the central nervous system (CNS) are uncertain, in part due to the poor specificity of currently
available C9orf72 antibodies.
Here, we generated and characterized novel knock-out validated monoclonal rat and mouse antibodies against
C9orf72. We found that C9orf72 is a low abundant, cytoplasmic, highly soluble protein with the long 481 amino
acid isoform being the predominant, if not exclusively, expressed protein isoform in mouse tissues and human
brain. As consequence of the C9orf72 repeat expansion, C9orf72 protein levels in the cerebellum were reduced to
80% in our series of C9orf72 mutation carriers (n = 17) compared to controls (n = 26). However, no associations
between cerebellar protein levels and clinical phenotypes were seen. Finally, by utilizing complementary
immunohistochemical and biochemical approaches including analysis of human iPSC derived motor neurons,
we identified C9orf72, in addition to its association to lysosomes, to be localized to the presynapses and able
to interact with all members of the RAB3 protein family, suggestive of a role for C9orf72 in regulating synaptic vesicle
functions by potentially acting as guanine nucleotide exchange factor for RAB3 proteins.
In conclusion, our findings provide further evidence for haploinsufficiency as potential mechanism in C9orf72
pathogenesis by demonstrating reduced protein levels in C9orf72 mutation carriers and important novel insights into
the physiological role of C9orf72 in the CNS. Moreover, the described novel monoclonal C9orf72 antibodies will be
useful tools to further dissect the cellular and molecular functions of C9orf72.
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Introduction
In 2011, abnormal expansion of a GGGGCC hexanucleo-
tide repeat in a predicted non-coding region of the chromo-
some 9 open reading frame 72 (C9orf72) gene was
identified as the most common genetic cause of familial
and sporadic forms of frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS) including families in
which both conditions co-occur [13, 40]. How the repeat
expansion in C9orf72 contributes to neurodegeneration is
currently unresolved. As for other repeat expansion muta-
tions, three non-exclusive pathogenic mechanisms have
been proposed: a toxic RNA gain of function by accumula-
tion of transcripts with expanded repeats in RNA foci that
bind and sequester specific RNA binding proteins resulting
in disruption of their function, a toxic protein gain of func-
tion through aberrantly expressed proteins generated by re-
peat associated non-ATG translation of transcripts with
expanded repeats, and haploinsufficiency as consequence of
expanded repeats altering expression of their hosting gene.
Based on studies using human tissues and model sys-
tems there is evidence for all three mechanisms being in
play for C9orf72 repeat expansions. First, RNA foci com-
posed of mutated sense and antisense C9orf72 tran-
scripts are present in up to 50% of neuronal nuclei in
key anatomical regions [12, 13, 15, 32]. RNAs with the
extended repeats are reported to fold into G quadruplex
structures able to bind several proteins [10, 19, 24, 34].
Second, GGGGCC repeat expansions in sense and anti-
sense transcripts have been shown to act as templates
for the synthesis of five aberrantly expressed dipeptide
repeat (DPR) proteins by repeat-associated non-ATG
translation. Neuronal inclusions composed of these DPR
proteins are highly specific neuropathological hallmark
features of C9orf72 mutation carriers [2, 15, 33, 35, 60]
and have shown neurotoxic effects in various model sys-
tems upon overexpression under artificial AUG start
codon [8, 29, 31, 37]. However, so far no consistent cor-
relation of RNA foci and DPR protein pathology with
the regional pattern of neurodegeneration and/or pres-
ence of TDP-43 pathology, the neuropathological hall-
mark feature of ALS and FTD including cases with
C9orf72 mutations [36], has emerged despite extensive
quantitative analysis [11, 12, 26, 27]. Thus, the patho-
genic relevancies of RNA foci and DPR proteins in dis-
ease pathogenesis remain to be clarified. Finally, the
potential role of haploinsufficiency is supported by the
consistent demonstration of decreased C9orf72 mRNA
levels in different tissues including postmortem brain
tissue of C9orf72 mutation carriers [13, 17, 52], motor
deficits reported in C9orf72 knockdown zebrafish [9] and
C.elegans [50] models as well as contribution of reduced
protein levels to neurodegeneration in induced human
motor neurons from C9orf72 mutation carriers [46]. How-
ever, the absence of obvious neurologic phenotypes in
C9orf72 knock-out mice argues against a sole role of hap-
loinsufficiency in disease pathogenesis [3, 23, 38, 47], al-
though it remains to be tested whether additional stressors
might be required as second hits to induce neurodegenera-
tion in these mouse models.
Further investigations on the potential contribution of
C9orf72 haploinsufficiency in disease pathogenesis of
ALS and FTD is hampered due to little knowledge about
the physiological functions of C9orf72. Based on bio-
informatics analysis, C9orf72 is predicted to contain dif-
ferentially expressed in normal and neoplastic cells
(DENN) domains [25, 59], that are characteristics of
guanine nucleotide exchange factors (GEFs) for specific
Rab GTPases (Rabs) [55, 58]. Rabs are key determinants
of organelle identities that switch between two conform-
ational states, an inactive form bound to GDP and an ac-
tive form bound to GTP. The conversion of GDP-bound
to GTP-bound Rabs is facilitated by GEFs and results in
enrichment of activated Rabs at distinct target membranes
where they recruit additional proteins in order to mediate
practically all membrane trafficking events in eukaryotes
[39]. In agreement with the bioinformatics prediction, re-
cent studies have shown that C9orf72 is part of a protein
complex containing Smith-Magenis syndrome chromo-
somal region candidate gene 8 (SMCR8) and WD repeat
containing protein 41 (WDR41) [1, 21, 45, 48, 51, 54, 57],
and that this complex possesses GEF activity for RAB8A
and RAB39B, two Rabs involved in autophagy [45, 57].
Accordingly, C9orf72 has been found to modulate differ-
ent steps of the autophagy and endo-lysosomal pathways
[1, 21, 45, 48, 51, 54, 57].
Beyond that, insights on functions of C9orf72 and
whether C9orf72 repeat expansions result in reduced
C9orf72 protein levels are so far limited in part due to poor
specificity of currently available C9orf72 antibodies with
conflicting and inconsistent results reported on its subcellu-
lar distribution and expressed isoforms. Importantly, since
the subcellular localization of a predicted GEF protein de-
termines where in the cell specific Rab-GTPases might be
activated, it is essential to gain further knowledge on the ex-
pression pattern of C9orf72 particularly in the central ner-
vous system (CNS) in order to dissect its functions.
Therefore, the aim of the present study was to gener-
ate and characterize novel antibodies against C9orf72
with the goal to investigate the subcellular distribution
and function of C9orf72 in the CNS and to test for hap-
loinsufficiency on the protein level in postmortem brain
tissue of ALS, ALS/FTD and FTD cases with C9orf72 re-
peat expansions.
Material and methods
Generation of monoclonal antibodies against C9orf72
Rat monoclonal antibodies (mAbs) were generated against
synthesized peptides corresponding to amino acid residues
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321–335 (peptide 1), 417–434 (peptide 2), 100–113 (pep-
tide 3), 140–155 (peptide 4) and 184–203 (peptide 5) of
human C9orf72 (Protein ID: Q96LT7) coupled to bovine
serum albumin (BSA) or ovalbumin (OVA) (Peptide Spe-
cialty Laboratories GmbH, Heidelberg, Germany). Lou/c
rats were immunized subcutaneously and intraperitoneally
with a mixture of 50 μg OVA-coupled peptides, 5 nmol
CpG 2006 oligonucleotide (Tib Molbiol, Berlin, Germany),
and an equal volume of incomplete Freund’s adjuvant.
After a 6 weeks interval, rats were boosted with 50 μg
OVA-coupled peptides in PBS. Hyperimmune spleen cells
were fused with the mouse myeloma cell line P3X63Ag8.653
using standard procedures. As primary screen supernatants
were screened in a solid-phase enzyme-linked immunosorb-
ent assay (ELISA) with the BSA-coupled peptides. Positive
supernatants were tested by immunoblot analysis using pro-
tein lysates from transiently transfected HEK293T cells. Cells
from identified and further characterized mAbs were sub-
cloned at least twice by limiting dilution. Experiments were
performed with cell culture supernatants from established
clones 12E7 (rat IgG1) against peptide 4, 5F6 (rat IgG1) and
12G10 (rat IgG1) against peptide 5, and 2H7 (rat IgG1) and
15C5 (rat IgG2a) against peptide 2. For generation of mouse
monoclonal antibodies, 100 μg of HIS-tagged C9orf72/
SMCR8/ WDR41 complex purified from baculovirus in-
fected insect SF2 cells and 200 μg of poly (I/C) as adjuvant
were injected intraperitoneally into 2 months old BALB/c fe-
male mice. Five injections were performed at 2 week inter-
vals. Spleen cells were fused with Sp2/0.Agl4 myeloma cells.
Hybridoma culture supernatants were tested by ELISA for
cross-reaction with GST-tagged C9orf72 purified from
BL21(RIL) pRARE E. coli. Positive supernatants were then
tested by immunofluorescence and immunoblot on lysates
from HA-tagged C9orf72 transfected HEK293T cells. Spe-
cific cultures were cloned twice on soft agar. One specific
clone 1C1 was established (mouse IgG1k), and ascites fluid
was prepared by injection of 2 × 106 hybridoma cells into
Freund adjuvant-primed BALB/c mice. Epitope mapping re-
vealed that 1C1 recognizes a region between amino acid
170–200 of human C9orf72. All animal experimental proce-
dures were performed according to the European authority
guidelines.
Other antibodies
Other primary antibodies used in this study included:
anti-C9orf72 (22637–1-AP, Proteintech Group; 66,140–1-Ig,
Proteintech Group; GTX119776, GeneTex; sc-138,763,
Santa Cruz; AP12928b, Abgent), anti-synaptoporin (102,002,
Synaptic Systems), anti-synaptophysin (101,002, Synaptic
Systems; M0776, Dako), anti-GAPDH (MAB374, Millipore),
anti-α-tubulin (T5168, Sigma), anti-RAB3 (107,003, Synaptic
Systems), anti-RAB3A (HPA003160, Atlas Antibodies),
anti-PSD-95 (ab18258, Abcam), anti-LAMP1 (ab24170,
Abcam), anti-LAMP2 (10397–1-AP, Proteintech Group),
anti-SMCR8 (1D2, homemade), anti-RAB39B (1H1, home-
made), anti-Histone H3 (ab21054, Abcam), anti-Cox IV
(ab16056, Abcam), anti-myc tag (2276 and 2272, Cell Signal-
ing), anti-FLAG tag (PA1-984B, Pierce), and anti-HA tag
(26,183, Pierce or 3F10, Merck).
Plasmids and constructs
pCMV6 containing C-terminally myc-DDK-tagged cDNAs
of human C9orf72 variant 1 (NM_145005), human C9orf72
variant 2 (NM_018325), mouse C9orf72 encoding for iso-
form 1 (NM_001081343), mouse C9orf72 encoding for iso-
form 2 (BC026738), C-terminally FLAG-tagged human
cDNAs of SMCR8, and Rab proteins were purchased from
OriGene. cDNAs for C9orf72 were subcloned into
pcDNA5/FRT/TO (Invitrogen) with or without myc-DDK-
tag. Optimized cDNA for human N-terminally HA-tagged
C9orf72 variant 1 cloned in pcDNA3 was described previ-
ously [45] and is available through Addgene.
Cell cultures and transfection
HEK293T cells were cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM) with Glutamax (Invitrogen) sup-
plemented with 10% (vol/vol) fetal calf serum (FCS,
Invitrogen) and penicillin/streptomycin (Invitrogen) at
37 °C with 5% CO2. Transfection of cells for immuno-
blot or immunofluorescence analysis was carried out
with Fugene HD (Promega) or calcium phosphate
method and indicated plasmids. Medium was exchanged
7 h after transfection and cells were examined 48 h after
transfection. For immunoprecipitation experiments
6.25 × 105 HEK293T cells were co-transfected for 24 h
with indicated plasmids using Fugene HD (Promega)
and further processed as described below.
Motor neurons were generated from human induced
pluripotent stem cells (iPSCs) as previously described
[28]. Briefly, iPSCs (clone 56c2, Phenocell) were dissoci-
ated with Accutase (Invitrogen) and resuspended in dif-
ferentiation medium N2B27 (DMEM F12, Neurobasal
vol:vol supplemented with N2 (Life Technologies), B27
(Life Technologies), Pen-strep 1%, β-mercapthoethanol
0.1% (Life Technologies), ascorbic acid (AA, 0.5 μM,
Sigma Aldrich)) with Y-27632 (5 μM, STemGent),
SB431542 (40 μM, Tocris), LDN 193189 (0.2 μM, Milte-
nyi) and Chir-99,021 (3 M, Tocris) for 2 days.
Chir-99,021 was maintained from day 0 to day 4 of dif-
ferentiation and SB431542/LDN 193189 from day 0 to
day 7. Differentiation medium was supplemented with
retinoic acid (RA, 100 nM, Sigma Aldrich) and smooth-
ened agonist (SGA, 500 nM, Calbiochem) at day 2 of dif-
ferentiation. At day 7, medium was changed for N2B27
supplemented with RA (100 nM), SAG (500 nM) and
BDNF (10 ng/ml). Two days later, DAPT (10 μM,
Tocris) was added. Ten days after the beginning of the
differentiation, cells were dissociated with Trypsin and
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plated on poly-ornithin/laminin coated glass coverslips
at a density of 33,000 cells per cm2 in N2B27 medium
containing RA (100 nM), SAG (500 nM), BDNF (10 ng/
ml) and DAPT (10 μM). Seven days later, DAPT was
withdrawn and replaced by GNDF (10 ng/ml). Cells
were analyzed by immunocytochemistry after 30 days of
differentiation.
Immunocytochemistry and immunofluorescence
HEK293T cells: Cells were fixed on coverslips for 15 min
in 4% paraformaldehyde (PFA) in PBS, permeabilized for
5 min in 0.25% Triton X-100 in PBS and subsequently
incubated for 1 h in blocking buffer (2% fetal bovine
serum and 0.1% Triton X-100 in PBS). Coverslips were
incubated overnight at 4 °C with the indicated C9orf72
mAbs and anti-myc antibodies diluted in blocking buf-
fer. After washing steps with PBS, coverslips were incu-
bated for 1 h at room temperature with Alexa Fluor
488- or 594-conjugated secondary antibodies (Invitro-
gen), washed with PBS, incubated in Hoechst 33342 for
5 min to stain nuclei, and mounted onto glass slides
using fluorescence mounting medium (Dako Agilent).
Human iPSC derived motor neurons: Glass coverslips
with plated cells were fixed in 4% PFA for 10 min and
subsequently washed three times with PBS. The cover-
slips were incubated for 10 min in PBS plus 0.5% Triton
X-100 and washed three times with PBS before incuba-
tion for 1 h with indicated primary antibodies (1C1,
12E7, SMCR8, LAMP1, LAMP2, RAB39B, RAB3, synap-
tophysin). Coverslips were washed twice with PBS before
incubation with a Cyanine 3-conjugated goat anti-rabbit,
anti-mouse or anti-rat and Alexa 488-conjugated donkey
anti-rat or anti-mouse secondary antibodies for 1 h,
washed with PBS, incubated for 2 min with DAPI (1/10000
dilution in PBS) and rinsed twice with PBS before mount-
ing onto glass slides using ProLong Mountant (Molecular
Probes). For quantification, hundred C9orf72-positive vesi-
cles per coverslip were counted and the mean and standard
deviation of co-localization was calculated from three inde-
pendent experiments.
Images were obtained with a fluorescence microscope
(Leica) equipped with a CCD camera.
Immunoprecipitation
Co-transfected HEK293T cells were scraped into radio-
immunoprecipitation assay (RIPA) buffer (50 mM Tris–
HCI pH 7.6, 150 mM NaCl, 1% NP-40) and centrifuged
for 15 min at 18,000 g at 4 °C; 20 μl of pre-washed HA
magnetic beads (Dynabeads) was added, and immuno-
precipitation was carried out for 1 h at 4 °C with constant
rotation. For immunoprecipitation of endogenous C9orf72
from mouse brains, 100 μl of mAb 1C1 was incubated with
mouse brain extract in RIPA buffer overnight at 4 °C.
Pre-cleared A/G magnetic beads (Life Technologies) were
added and immunoprecipitation was carried out for 3 h at
4 °C with constant rotation.
After three washes of beads with washing buffer (50 mM
Tris–HCI pH 7.6, 150 mM NaCl, 0.05% Tween), bound
proteins were eluted by boiling in SDS–PAGE loading buf-
fer at 95 °C for 5 min and analyzed by immunoblot using
the indicated antibodies.
Mouse tissue
C57BL/6 N mice were bred in our facilities. Animals
were euthanized using CO2, organs were removed and
further processed for histological and biochemical ana-
lysis. Brain tissue from C9orf72 knock-out mice (C9−/−;
n = 3) described previously [47] and non-transgenic lit-
termates (C9+/+; n = 3) were kindly provided by the Pas-
terkamp lab for knock-out validation experiments of
C9orf72 mAbs. All animal experiments were carried out
in accordance with the institutional and European au-
thority guidelines.
Human postmortem tissue
Human post mortem tissues were obtained from the
brain banks affiliated with the University of Tübingen
and the University of British Columbia. Consent for aut-
opsy was obtained from probands or their legal repre-
sentative in accordance with local institutional review
boards.
The study cohort consisted of 18 cases with a C9orf72
repeat expansion mutation (C9+) covering the complete
clinical spectrum presenting with ALS (n = 6), FTD/ALS
(n = 5) or FTD (n = 7) and 33 control cases (C9-) con-
sisting of neurologic disease controls with TDP-43 path-
ology in the absence of a C9orf72 repeat expansion
mutation clinically presenting with ALS (n = 16), ALS/
FTD (n = 6) and FTD (n = 5), three neurologically
healthy controls, two Alzheimer’ disease cases and one
case with hypoxic encephalopathy. C9orf72 repeat ex-
pansions have been identified by genetic testing using
repeat-primed PCR or were inferred from the presence
of DPR protein pathology. Details for cases are provided
in Additional file 1: Table S1.
Immunohistochemistry and in situ hybridization
Immunohistochemistry on mouse and human CNS tis-
sue was performed on 2–5 μm thick sections of formalin
fixed, paraffin-embedded (FFPE) tissue using the Ven-
tana BenchMark XT automated staining system with the
iVIEW DAB detection kit (Ventana).
To establish a protocol for the immunohistochemical
detection of C9orf72, mAb 1C1 and 12E7 were first tested
on sections from C9+/+ and C9−/− mouse brains (forma-
lin fixation: 24 h) with different dilutions and different
antigen pretreatments (boiling for 60 min in CC1 or CC2
buffer (Ventana), or no pretreatment). A specific, knock-out
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validated signal was obtained in mouse brains for mAb 1C1
using 1:100 dilution and boiling for 60 min with CC1 buffer
as pretreatment and this protocol was used for further ex-
periments in this study.
To test for the immunohistochemical detection of
C9orf72 in human postmortem FFPE brain tissue, hippo-
campus, frontal cortex and cerebellum sections (n = 3 C9+
and n = 3 C9- cases, formalin fixation times ranging from
2 weeks to several months) were stained with the above
described protocol for 1C1; however, no immunoreactivity
was observed. To test for the influence of formalin fixation
times on C9orf72 immunoreactivity, mouse brains (n = 2)
were fixed in formalin for 12, 24, 48, 72 or 96 h before
paraffin embedding and sections stained using the above
described 1C1 protocol. Best signals were obtained for 12
and 24 h fixation time points, while a dramatic reduction
in immunoreactivity was observed with increasing forma-
lin fixation times. No improvement of 1C1 immunoreac-
tivity signals could be achieved in the > 24 h formalin
fixed mouse tissues by testing additional pretreatments
(boiling for 90 min in CC1 or CC2 buffer (Ventana), en-
zymatic digestion with Protease 1 and 2 (Ventana), or for-
mic acid treatment for 5 min).
No specific signal could be detected in mouse FFPE
sections using mAb 12E7 with any tested pretreatment
in mouse tissue, indicating that its epitope is masked in
FFPE tissue. Subsequently, no staining was observed for
12E7 in human postmortem FFPE tissue.
Human C9orf72 specific antibodies 5F6 and 12G10
were tested in parallel on mouse brain sections (used as
negative control) and human postmortem hippocampus
and cerebellum sections with different dilutions and pre-
treatments (boiling for 60 min in CC1 or CC2 buffer
(Ventana), or no pretreatment). However, all conditions
resulted in similar staining profiles in human and mouse
tissue due to cross-reactivity with unrelated proteins
(Additional file 1: Figure S1). Additional antibodies for im-
munohistochemistry included polyclonal rabbit anti-
synaptoporin, anti-synaptophysin and LAMP1.
In situ hybridization was performed on FFPE mouse sec-
tions using the RNAscope® 2.5 HD Reagent Kit-RED (Ad-
vanced Cell Diagnostics) according to the user manuals
322,452-USM and 322,360-USM. The target region of the
probe (Mm-3110043O21Rik) corresponds to nucleotides
601–1539 of mouse C9orf72 mRNA (NM_001081343).
RIPA lysates
Mouse tissues and human postmortem brain tissues
were homogenized in RIPA buffer (50 mM Tris-HCl,
150 mM NaCl, 1% (v/v) octylphenoxy poly(ethyleneox-
y)ethanol (IPEGAL), 5 mM EDTA, 0.5% (w/v) sodium
deoxycholate, 0.1% (w/v) sodium dodecyl sulfate (SDS),
pH 8.0) at 1 g/2 ml ratio. Lysates were passed through
18 and 21 Gauge needles and sonicated to shear nucleic
acids. Cellular debris was removed by centrifugation for
2 min at 3000×g at 4 °C and supernatant collected as
RIPA lysate. Transfected cells were scraped into RIPA
buffer and subjected to brief sonication on ice. Cell deb-
ris was removed by centrifugation for 5 min at 12,000×g
at 4 °C. Protein concentration was determined using the
Pierce™ BCA Protein Assay Kit (Thermo Fisher Scien-
tific) according to the manufacturer’s recommendations.
Subcellular fractionations
Cytoplasmic and nuclear proteins from mouse brains
were extracted as previously described [18]. Briefly, fore-
brain tissue from wild-type mice was dounce homoge-
nized in buffer containing 10 mM HEPES, 10 mM NaCl,
1 mM KH2PO4, 5 mM NaHCO3, 5 mM EDTA, 1 mM
CaCl2, 0.5 mM MgCl2 supplemented with protease in-
hibitors (1 g/10 ml ratio). After 10 min incubation on
ice, sucrose was added to a final concentration of
125 mM. An aliquot was collected representing whole lys-
ate, and the remaining homogenate was centrifuged for
10 min at 1000×g at 4 °C. The supernatant was collected
as cytoplasmic fraction. The pellet was washed in TSE
buffer (10 mM Tris, 300 mM sucrose, 1 mM EDTA, 0.1%
IPEGAL supplemented with protease inhibitors) and cen-
trifuged for 12 min at 6250×g at 4 °C. The supernatant
was removed and the pellet was washed twice in TSE buf-
fer and centrifuged for 10 min at 4000×g at 4 °C. The final
pellet was re-suspended in RIPA buffer containing 2%
SDS by sonication and collected as nuclear fraction.
Enrichment of synaptosomal compartments from
mouse forebrain was performed according to previously
described protocols [7, 16, 20] with minor modifications
(see schematic presentation Fig. 2e). Briefly, mouse fore-
brains were homogenized in 5 volumes of ice-cold buff-
ered sucrose (0.32 M sucrose, 4 mM HEPES-NaOH,
pH 7.3) using a Dounce tissue grinder with tight-fitting
glass pestle (Wheaton). The homogenate was centrifuged
for 5 min at 1000×g at 4 °C. The pellet (P1) containing
cellular debris and nuclei was discarded, and the post-
nuclear supernatant (S1) was centrifuged for 15 min at
12,500×g. The supernatant (S2; synaptosome depleted
fraction containing cytosol and microsomes) was re-
moved, and the pellet (P2) representing the crude synap-
tosomal fraction was washed in buffered sucrose and
centrifugation repeated as above. For preparation of
crude synaptic vesicles, P2 was resuspended in buffered
sucrose, and subjected to osmotic lysis by adding 9 vol-
umes of ice-cold water. After three Dounce strokes, 1 M
Tris-HCl pH 7.5 was added to a final concentration of
10 mM. After 30 min incubation on ice, the suspension
was centrifuged for 20 min at 25,000×g to yield a lysate
pellet (LP1, enriched in presynaptic membrane proteins)
and a lysate supernatant (LS1). LS1 was further centri-
fuged for 2 h at 174000×g to yield LS2 containing the
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soluble synaptosomal content and LP2 representing the
crude synaptic vesicle (SV) fraction.
For preparation of postsynaptic densities (PSDs) the
washed P2 fraction was suspended in solution B (0.32 M
sucrose, 1 mM NaHCO3) by six Dounce strokes. Eight
ml of the resuspended P2 was loaded on a discontinuous
sucrose gradient (10 ml each of 0.85, 1.0, and 1.2 M su-
crose solutions containing 1 mM NaHCO3) and centri-
fuged for 2 h at 82,500×g. The fraction between 1.0 and
1.2 M sucrose containing synaptosomes was collected
and diluted with solution B. An equal volume of 1% Tri-
ton X-100 in 0.32 M sucrose, 12 mM Tris-HCI pH 8.1
was added, the suspension incubated for 15 min at 4 °C
under continuous stirring and then centrifuged for
20 min at 32,800×g. The pellet (P3) was resuspended in
solution B, and was layered on a sucrose gradient (com-
posed of 4 ml of 2 M sucrose, 3 ml of 1.5 M sucrose,
and 3.0 ml of 1 M sucrose solutions containing 1 M
NaHCO3) and centrifuged for 2 h at 201,800×g. The
fraction between 1.5 and 2.0 M sucrose was collected
and diluted to a final volume of 2 ml with solution B.
An equal volume of 1% Triton X-100, 150 mM KCI was
added and the suspension was centrifuged for 20 min at
201,800×g. The resulting pellet P4 containing PSDs was re-
suspended in solution B. For immunoblot analysis, 50 μg
total protein per fraction were loaded for C9orf72 detec-
tion and 20 μg for detection of other marker proteins.
Biochemical analysis of human postmortem brain tissue
The sequential extraction of proteins with buffers of in-
creasing stringency from fresh-frozen postmortem frontal
cortex from C9orf72 mutation cases (n = 2) and controls
(n = 4) was performed as described previously [36]. Briefly,
gray matter was extracted at 5 ml/g (v/w) with low-salt
(LS) buffer (10 mM Tris, pH 7.5, 2 mM EDTA, 1 mM di-
thiothreitol (DTT), 10% sucrose, and a cocktail of protease
inhibitors), high-salt (HS) buffer (50 mM Tris, pH 7.5,
0.5 M NaCl, 2 mM EDTA, 1 mM DTT, 10% sucrose) with
1% Triton X-100, myelin flotation buffer (HS buffer con-
taining 30% sucrose), and Sarkosyl (SARK) buffer (HS buf-
fer + 1% N-lauroyl-sarcosine). The detergent-insoluble
material was finally extracted in 0.25 ml/g of urea buffer
(7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)di-
methylammonio]-1-propanesulfonate, 30 mM Tris, pH 8.5).
Equal amounts of protein fractions per case (10 μl for LS,
HS, SARK and UREA) were analyzed by immunoblot. For
quantification of C9orf72 levels, RIPA lysates were generated
from frozen postmortem cerebellum (n = 17 C9+, n = 26
C9-) and frontal cortex (n = 10 C9-) and analyzed by
immunblot analysis as described below. To correlate
C9orf72 expression in frontal cortex with levels of neurode-
generation frontal cortex sections were assessed on H&E
stains and neurodegeneration/cell death graded as absent
(0), mild (1), moderate (2) or severe (3) based on the pres-
ence of spongiosis, neuronal loss, and gliosis.
Immunoblot analysis
Proteins were separated by SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE). With the exception of immunoblots
for the quantification of C9orf72 levels in human lysates, im-
munoblots were performed using enhanced chemilumines-
cence detection. Therefore, proteins were transferred to
either polyvinylidene difluoride membranes (Millipore) or
nitrocellulose membranes (GE Healthcare). Membranes
were blocked with Tris buffered saline containing 3–5%
non-fat dry milk and incubated with indicated primary anti-
bodies overnight at 4C. Bound antibodies were detected
with horseradish peroxidase-conjugated anti-rat IgG (H+
L), anti-mouse IgG (H+L), anti-mouse IgG (light chain spe-
cific) or anti-rabbit IgG (H+ L) and signals were visualized
with the chemiluminescence detection reagents Luminata
Forte (Millipore) or Amersham ECL Prime (GE Healthcare).
Precision Plus Protein Dual Color Standards (Biorad) or
PageRule Plus Prestained Protein Ladder, 10 to 250 kDa
(ThermoFisher) were used as molecular weight size marker.
Semi-quantitative immunoblot analysis of human tis-
sues was performed using fluorescence detection and
the Odyssey® CLx Imaging System (LI-COR Biosciences).
Proteins were transferred to nitrocellulose membranes
and blocked with Odyssey blocking buffer (LI-COR Bio-
sciences). Antibodies were detected with IRDye800CW
or 680RD conjugated anti-rat or anti-mouse IgG
(LI-COR). The linear range for C9orf72 detection was
determined by serial dilutions of RIPA lysate and conse-
quently 50 μg of RIPA lysates per lane were loaded for
analysis. Total protein stains of membranes (BLOT-Fast-
Stain, G-Biosciences) were used as loading controls for
normalization. This has been shown to be more suitable
over measuring housekeeping genes such as GAPDH
and is the recommended approach for normalization,
particularly when loading of high amount of proteins
per lane is necessary as is the case for the detection of
C9orf72 [14]. Signal intensities for C9orf72 and total
protein stains were analysed using the Image Studio™
software (LI-COR).
Statistical analysis
Statistical analysis was performed with the GraphPadPr-
ism software (version 7.01 for Windows). Student’s t test
(two-tailed) was used for comparison of two groups and
one-way ANOVA was used for comparison of multiple
groups followed by Tukey honestly significant difference
(HSD) post hoc test. Associations between age at death,
disease duration, postmortem delay and neurodegenera-
tion with C9orf72 levels were analyzed by Spearman’s
rank correlation coefficient. Significance level was set at
p < 0.05.
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Results
Characterization of highly specific novel monoclonal
C9orf72 antibodies
Novel rat and mouse monoclonal antibodies (mAbs)
against C9orf72 were generated and characterized recog-
nizing 4 different epitopes of the human C9orf72 protein
sequence (Fig. 1a, Table 1). The specificity of identified
mAbs was first demonstrated by immunoblot analysis of
protein lysates from HEK293 cells transiently expressing
either untagged or myc-DDK-tagged human C9orf72
short (C9-S) and long (C9-L) isoforms as well as murine
C9orf72 isoform 1 (mC9–1) and isoform 2 (mC9–1)
(Fig. 1b; Additional file 1: Figure S1a). In line with the
respective epitopes recognized by the different mAbs,
rat clone 12E7 detected C9-S, C9-L and mC9–1; mouse
clone 1C1 detected C9-S, C9-L, mC9–1 and mC9–2; rat
clones 5F6 and 12G10 specifically labeled human C9-S
and C9-L but not murine C9orf72; and rat clones 2H7
and 15C5 labeled C9-L, mC9–1 and mC9–2 but not
C9-S. However, clones 2H7 and 15C5 also revealed a
strong unspecific band below 50 kDa of the size of un-
tagged C9-L, limiting their usefulness for further studies.
Immunoblot analyses were confirmed by double-label
immunofluorescence of HEK293 cells transiently express-
ing myc-DDK-tagged C9-S, C9-L or mC9–1. Complete
co-localization of the diffuse cytoplasmic C9orf72 staining
was seen between anti-myc and anti-C9orf72 mAbs 12E7
and 1C1 for C9-S, C9-L, while mAbs 15C5 and 2H7 only
recognized C9-L but not C9-S and mAbs 5F6 and 12G10
recognized specifically human but not murine C9orf72
(Fig. 1c, data not shown). Further validation of the specifi-
city of our antibodies to detect C9orf72 was performed by
immunoblot analysis of whole brain protein lysates of
wild-type mice and C9orf72 knock-out mice. A single
band around 50 kDa was obtained for rat mAb 12E7 and
mouse mAb 1C1 in wild-type mice corresponding in size
to the expected molecular weight of the murine C9orf72
isoform 1 (Fig. 1d; Additional file 1: Figure S1b). Notably,
no additional bands were observed at the expected mo-
lecular weight size for the postulated murine isoforms 2
and 3, although based on the recognized epitope of 1C1
all murine isoforms should be recognized and absence of
isoform 2 was further demonstrated with the C-terminal
mAb 15C5 (Additional file 1: Figure S1c). These results in-
dicate that the 481 amino acid long murine isoform 1,
which is the equivalent isoform to C9-L in humans,
is the predominantly expressed C9orf72 isoform in
the mouse CNS. Importantly, this 50 kDa band was
absent in lysates of C9orf72 knock-out mice, confirm-
ing the specificity of our mAbs 1C1 and 12E7 to de-
tect C9orf72.
Of technical interest, none of the tested commercially
available C9orf72 antibodies used in previous studies re-
vealed a comparably high specificity for detecting C9orf72
in our knock-out validation experiments using C9orf72
−/− mouse brain (Additional file 1: Figure S2).
Thus, we generated novel C9orf72 mAbs with knock-out
validated specificity as valuable and powerful tools for fur-
ther analysis of C9orf72 protein expression and localization.
C9orf72 protein is enriched at the presynapse and co-
localizes with a subset of synaptic vesicles in human iPSC-
derived neurons in addition to its localization to lysosomes
By comparing different tissues of wild-type mice, C9orf72
protein was found to be expressed as long isoform at high-
est levels in the CNS (brain and spinal cord), at medium
levels in tissue of the immune system (spleen) and at low
levels in lung, heart, liver, kidney and skeletal muscle
(Fig. 2a). These data are in agreement with transcriptome
profiles reported in databases [30] and results in trans-
genic mice with targeted LacZ insertion into the C9orf72
locus [49]. Expression levels of different mouse brain re-
gions did not reveal obvious regional differences (Fig. 2b).
In nuclear-cytoplasmic fractionation experiments of mouse
brain tissue, C9orf72 was exclusively found in the cytosolic
protein fraction (Fig. 2c). Interestingly, when we evaluated
the expression levels of C9orf72 in the CNS over a time
course from postnatal day 1 to 300 (n = 3), we noticed an
increase of C9orf72 levels within the first 2 postnatal weeks
while after that period no significant changes were observed
in C9orf72 expression levels (Fig. 2d). Since this time period
with increase of C9orf72 expression coincides with the on-
set of synaptogenesis and synapse maturation, we specu-
lated that C9orf72 might be localized at the synapse.
To test this hypothesis, subcellular fractionations ac-
cording to well-established protocols for the enrichment
of synaptosomal compartments [7, 16, 20] were per-
formed with adult mouse brain as illustrated schematic-
ally in Fig. 2e. Interestingly, a significant fraction of
C9orf72 was found to be present in the crude synapto-
somal fraction P2 (Fig. 2f and g) and in the pure synap-
tosomal fraction after sucrose gradient centrifugation
(Fig. 2g). After hypotonic lysis of synaptosomal fraction
P2 and centrifugation steps, C9orf72 was found to be re-
leased into LS2, a fraction enriched for soluble cytoplas-
mic contents of synaptosomes, while C9orf72 was not
present in fraction LP2 enriched for synaptic vesicles
(SVs) (Fig. 2f ) or in the Triton-extracted PSD fraction P4
(Fig. 2g). Analysis of control proteins for specific frac-
tions revealed expected distribution patterns, with en-
richment of synaptophysin in the crude SV fraction LP2
as expected for an integral membrane part of synaptic
vesicles, and enrichment of PSD-95 in pure PDS frac-
tions P4 and in LP1 enriched for synaptosomal heavy
membranes (Fig. 2f and g), thereby validating the quality
of our extractions.
In line with our biochemical data, immunohistochem-
istry for C9orf72 performed with mAb 1C1 in mouse
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brain sections revealed a fine punctate immunoreactivity
in the neuropil consistent with a synaptic staining pat-
tern throughout the CNS, although with variable signal
intensities (Fig. 3). Specifically, C9orf72 expression was
most pronounced in the entire hippocampal mossy fiber
system with strong labeling in the hilus, stratum lucidum
and the infrapyramidal fiber bundles (Fig. 3a and b). This
strikingly resembles the staining pattern seen for other
presynaptic marker proteins such as synaptophysin and
synaptoporin, a synaptic vesicle protein with an expression
Fig. 1 Basic characterization of novel monoclonal antibodies against C9orf72. a Schematic representation of postulated human and murine C9orf72
protein isoforms with epitopes recognized by novel monoclonal antibodies (mAbs) against C9orf72. In humans, two C9orf72 protein isoforms are
postulated with isoform 1 representing a 481 amino acid protein, also known as long isoform or C9-L (transcribed by transcript variant 2 with the GGGG
CC repeat located in the promoter region and transcript variant 3 with the GGGGCC repeat located in the first intron); and isoform 2 representing a 222
amino acid protein, also known as short isoform or C9-S (transcribed by transcript variant 1 with the GGGGCC repeat located in the first intron). In mice,
three protein isoforms are postulated, with isoform 1 corresponding in size to human C9-L with 98% similarity on amino acid sequence. The red lines in
the murine isoforms illustrate two amino acid changes between the human and mouse C9orf72 sequence in the epitope recognized by mAbs 5F6 and
12G10. b Immunoblot analysis of protein lysates of HEK293 cells expressing untagged or myc-DDK-tagged human C9-L and C9-S or myc-DDK-tagged
murine C9orf72 isoform 1 (mC9–1) with novel C9orf72 mAbs. Clones 12E7 and 1C1 recognize hC9-S and hC9-L as well as mC9–1. Clones 5F6 and
12G10 specifically recognize human but not mouse C9orf72. Clones 2H7 and 15C5 specifically recognize an epitope in the C-terminus only present in
hC9-L and mC9–1 but not hC9-S, however, both mAbs also recognize an unspecific band (asterisk). c Double label immunofluorescence for anti-myc
(green) and anti-C9orf72 (red) of HEK293 cells transiently expressing myc-DDK-tagged hC9-L, hC9-S or mC9–1 confirms the specificity of the indicated
mAbs for specific C9orf72 isoforms or species. Hoechst 33342 staining of nuclei (blue) in the merged images. Scale bar: 20 μm. d Immunoblot analysis
of total protein lysates from brains of wild-type (C9+/+) and C9orf72 knock-out (C9−/−) mice. Only a single band around 50 kDa corresponding in size to
the murine isoform 1 is detected with mAbs 12E7 and 1C1 in wild-type mice (arrowhead). Note, that this band is completely absent in C9−/− mice,
validating the high specificity for C9orf72 of the mAbs 12E7 and 1C1. The weak band labeled with an asterisk seen in C9−/− with the mouse mAb 1C1
represents mouse IgG heavy chain recognized by the anti-mouse IgG (H + L) detection antibody (see Additional file 1: Figure S1b for secondary
antibody control). GAPDH is shown as loading control. MW size marker: Precision Plus Protein Dual Color Standards (b and d)
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pattern mainly restricted to the mossy fiber system (Fig. 3k),
a finding further confirmed by double-label immunofluores-
cence for C9orf72 and synaptoporin (Additional file 1: Figure
S3a). A strong neuropil staining was also seen in the globus
pallidus (Fig. 3c and d), while weaker immunoreactivity was
present in the caudate-putamen (Fig. 3c), throughout the
cortex (Fig. 3e and f) and in the molecular layer of the
cerebellum (Fig. 3g). In addition to the punctate neuropil
staining, particularly large motor neurons in the brain stem
and spinal cord (Fig. 3h) demonstrated staining of small
dots in the cytoplasm consistent with staining of small ves-
icles. These vesicles did not stain with antibodies against
synaptophysin and LAMP1 (data not shown) and thus
their nature remains to be identified. No labeling of nuclei
Table 1 Summary of basic characterization of novel monoclonal C9orf72 antibodies
Clone (species)
1C1 (mouse) 12E7 (rat) 5F6 (rat) 12G10 (rat) 2H7 (rat) 15C5 (rat)
detection of recombinant proteins
C9-L yes yes yes yes yes yes
C9-S yes yes yes yes no no
mC9–1 yes yes no no yes yes
mC9–2 yes no no no yes yes
knock-out validated yes yes na na no# no#
C9-L, long human C9orf72 isoform; C9-S, short human C9orf72 isoform; mC9–1, long murine C9orf72 isoform 1; mC9–2, murine C9orf72 isoform 2; na, not
applicable; #unspecific band at similar molecular size of endogenous long C9orf72 isoform
Fig. 2 C9orf72 is enriched in synaptosomes. a Immunoblot analysis of total protein lysates of different mouse tissues reveals widespread C9orf72 protein
expression detected as single band around 50 kDa with highest expression levels in brain followed by spinal cord. GAPDH is shown as loading control. b
No obvious changes are observed between different brain regions by immunoblot analysis of protein lysates from cortex, hippocampus, striatum,
cerebellum and spinal cord. GAPDH is shown as loading control. c Immunoblot analysis of nuclear and cytoplasmic protein fractionations extracted from
adult mouse brain reveals localization of C9orf72 to the cytoplasm. α-tubulin and Histone H3 are shown to demonstrate purity of the cytoplasmic and
nuclear fractions, respectively. d Immunoblot analysis and quantification of C9orf72 expression levels over mouse brain development from P1 to P300
showing increase of C9orf72 between P1 and P16. e Schematic of the purification protocols for synaptic vesicles and postsynaptic densities (PSDs).
Mouse forebrains were homogenized and centrifuged to generate a crude synaptosomal fraction (P2). P2 fractions were fractionated into synaptosomal
heavy membranes (LP1), synaptic vesicles (LP2), and synaptic cytosol (LS2) by hypotonic lysis and differential centrifugation. Alternatively, P2 fractions
were centrifuged through sucrose gradient to reveal a pure synaptosomal fraction which was further processed to isolate pure PSDs. f C9orf72 is
detectable in the synaptosomal fraction P2, and is released into the LS2 fraction containing the soluble cytoplasmic content of synaptosomes. g C9orf72
is enriched in the pure synaptosomal fraction, but absent from PSD fractions. f and g The purity of fractions was confirmed with specific marker proteins
for synaptic vesicles (synaptophysin), postsynaptic densities (PSD-95), mitochondria (Cox-IV), and lysosomes (Lamp1). MW size marker: PageRule Plus
Prestained Protein Ladder (a); Precision Plus Protein Dual Color Standards (b-d, f, g)
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and, no immunoreactivity in the white matter and glial cells
was detectable. The expression pattern is in good agree-
ment with our in situ hybridization experiments showing
widespread and predominant C9orf72 mRNA expression in
neurons with strongest signals in the dentate granule cells
but not in glial cells (Additional file 1: Figure S3b). Import-
antly, the specificity of the observed immunoreactivity for
C9orf72 with mAb 1C1 was validated by immunohisto-
chemical analysis of C9orf72 knock-out mouse brain sec-
tions showing absence of immunoreactivity (Fig. 3i, j;
Additional file 1: Figure S2f). In contrast, all tested com-
mercially available C9orf72 antibodies revealed similar
staining intensities and patterns in wild-type and C9orf72
knock-out mice (Additional file 1: Figure S2f).
Unfortunately, we failed to detect reliable immunore-
activity in routinely sampled FFPE human postmortem
CNS tissue using the established knock-out validated
protocol for mAb 1C1 on mouse tissue. Since we ob-
served that formalin fixation times > 24 h dramatically
diminished C9orf72 immunoreactivity signals with 1C1
also in mouse tissue, this is most likely due to the long
formalin fixation times (weeks to months) of available
human postmortem tissue (for details see Material and
Methods). Furthermore, a cross-reactivity of the human
specific C9orf72 antibodies 5F6 and 12G10 with add-
itional proteins as shown in brain lysates and tissue sec-
tions (Additional file 1: Figure S1d and e) prevented
their suitability for immunohistochemical analyses.
Thus, to address the localization of C9orf72 in human
neurons, we analyzed motor neurons differentiated from hu-
man iPSCs. Both knock-out validated C9orf72 antibodies
(1C1 and 12E7) revealed presence of C9orf72 in cytoplasmic
puncta with complete overlap of signals for both antibodies
(Additional file 1: Figure S4a). Double-label immunofluores-
cence revealed co-localization of C9orf72 with SMCR8 in al-
most all C9orf72 positive puncta (90 ± 9%) (Fig. 4),
consistent with the tight association reported between
these two proteins in co-immunoprecipitation experiments
Fig. 3 C9orf72 immunohistochemistry reveals synaptic staining pattern with enrichment in hippocampal mossy fiber terminals. Immunohistochemistry
with anti-C9orf72 mAb 1C1 (a-j); immunohistochemistry with anti-synaptoporin antibody (k). In the adult mouse brain (a-h), strong immunoreactivity for
C9orf72 is seen in the hippocampal mossy fiber system (a) with labeling in the hilus (asterisk), stratum lucidum (arrow) and infrapyramidal mossy fiber
bundles (arrowhead). (b) Higher magnification of punctate staining pattern of mossy fiber terminals in suprapyramidal (SPB) and infrapyramidal (IPB)
mossy fiber bundles. Robust staining was also observed in the globus pallidus (GP) (c and d) while the caudate putamen (CPu) (c) and other gray matter
regions showed weaker immunoreactivity of the neuropil as shown for frontal cortex (e and f) and cerebellum with predominant staining in the
molecular and granular layer (g). No immunoreactivity is seen in the white matter and internal capsule (ic). In addition to punctate neuropil staining,
neurons with large cytoplasm such as motor neurons in the spinal cord showed several cytoplasmic puncta (h). (i and j): Specificity of anti-C9orf72
immunohistochemistry was validated by the complete absence of immunoreactivity in brain sections from C9orf72 knock-out mice as shown for
hippocampus (i) and cerebellum (j). Note the strikingly similar staining pattern of the mossy fiber terminals in the hippocampus for C9orf72 (a) and for
the presynaptic marker protein synaptoporin (k). Scale bar: 533 μm (c); 400 μm (a, i, k); 267 μm (e); 80 μm (d, j, insert k); 40 μm (b, f, g); 20 μm (h);
6,5 μm (insert h)
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[1, 21, 45, 48, 51, 54, 57]. Further analysis showed
co-localization of C9orf72 with LAMP1 and LAMP2
(Fig. 4) in a subset of C9orf72 positive puncta (41 ± 8%), in-
dicating that a fraction of C9orf72 is present at lysosomes,
consistent with previous observations [1, 46]. Finally, in
agreement with our above described findings of a pre-
synaptic localization of C9orf72 in mouse CNS, a fraction
(11 ± 4%) of C9orf72 positive puncta co-labelled with
synaptophysin used as marker for SVs (Fig. 4) and a com-
parable co-localization was seen between SMCR8 and
synaptophysin (Additional file 1: Figure S4b). However,
only a subset (7 ± 3%) of synaptophysin positive SVs was
found to co-label with C9orf72, consistent with a transient
interaction of C9orf72 with SVs as indicated by our bio-
chemical fractionation experiments. Overall, our data im-
plicate an association of C9orf72 with SVs in mouse and
human neurons in addition to its association with lyso-
somes and vesicles of yet unknown identity.
C9orf72 interacts and co-localizes with all members of the
RAB3 protein family
Based on our biochemical and immunohistochemical
analyses, the subcellular distribution of C9orf72 is con-
sistent with it being a presynaptic terminal associated
protein with a transient and reversible interaction with
SVs. Given the described function of C9orf72 as GEF for
RAB8A and RAB39B, we speculated that C9orf72 might
be able to interact with specific Rabs present at SVs.
Thus, we performed immunoprecipitation experiments
in HEK293 cells co-expressing HA-tagged C9orf72 and
SMCR8 and various FLAG-tagged Rabs (Fig. 5a). Excit-
ingly, an interaction of the C9orf72/SMCR8 complex
was seen with all members of the RAB3 protein family
(RAB3A, RAB3B, RAB3C, RAB3D), which are Rabs
abundantly present at SVs (Fig. 2f ) and known to play
key roles in neurotransmitter release [6]. As controls, inter-
actions of the C9orf72/SMCR8 complex with RAB39B and
all members of the RAB8 subfamily (RAB8A, RAB10,
RAB13 and RAB15) were identified, comparable to interac-
tions previously described [45]. Importantly, immunopre-
cipitation of C9orf72 in wild-type mouse brain lysate
confirmed the interaction between endogenous C9orf72
and endogenous RAB3 (Fig. 5b). Consistently, double-label
immunofluorescence of human iPSC derived motor neu-
rons revealed a partial co-localization of C9orf72 with
RAB3 and RAB39B, which was used as positive control
(Fig. 5c and d). The interaction of C9orf72 with RAB3 pro-
teins is likely to be transient as only a subset (8 ± 3%) of
C9orf72 positive puncta co-localized with RAB3 and con-
versely, only a subset (5 ± 3%) of RAB3-positive vesicles
co-labeled with C9orf72 (Fig. 5d). Thus, our data suggest a
potential novel function of C9orf72 by acting as GEF for
RAB3 proteins.
C9orf72 protein expression levels are reduced in the
cerebellum as consequence of C9orf72 repeat expansions
To investigate the effect of C9orf72 repeat expansions
on protein expression, we decided to focus for our
Fig. 4 C9orf72 co-localizes with synaptic vesicles in human iPSC derived motor neurons. a C9orf72 positive puncta (green) are seen in the axons
of 30 day old human iPSC derived motor neurons which consistently co-localize with SMCR8 (red, upper panel) and partially co-localize with
LAMP2 as lysosomal marker (red, middle panel) or with the synaptic vesicle marker synaptophysin (red, lower panel). Nuclei are stained with DAPI
(blue) in the merged images. C9orf72 labeled with 12E7 antibody in the upper panel and with 1C1 in the middle and lower panel. b Graph
showing the percentage of C9orf72 positive puncta co-localizing with SMCR8, LAMP2 or synaptophysin. Values are shown as mean ± SD
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quantitative immunoblot analysis on cerebellum as brain
region, since it is a region known to express high levels
of C9orf72 mRNA [40] and shows consistent and robust
changes in transcript levels between C9orf72 mutation
carriers and controls [52, 53]. Moreover and in line with
our results showing a predominant neuronal C9orf72
expression, we observed a strong negative correlation
(rho = − 0.834, p = 0.004, Spearman rank correlation)
between C9orf72 protein expression and the level of
neurodegeneration/cell death in a pilot experiment on
frontal cortex samples from selected cases with no
C9orf72 mutation (Additional file 1: Figure S5), These
results highlight the potential bias that neuronal cell loss
may blur the interpretation of changes in C9orf72 protein
levels. Therefore, we considered that the cerebellum, a re-
gion not affected by overt neurodegeneration in ALS and
FTD, is best suited for the analysis of C9orf72 mutation
specific consequences on its own protein levels by avoiding
misinterpretation of changes related to neuronal cell loss.
The analyzed cohort consisted of n = 17 C9orf72 muta-
tion carriers covering the complete clinical spectrum
from pure ALS, mixed ALS/FTD and pure FTD and n =
26 neurologic disease controls (ALS, ALS/FTD and FTD
cases without C9orf72 mutation) with detailed informa-
tion on each case given in Additional file 1: Table S1.
There were no significant differences in the demograph-
ics between both cohorts. Immunoblot analysis of total
RIPA protein lysates extracted from cerebellum revealed
that C9orf72 is a low abundant protein detectable as sin-
gle band of ~ 50 kDa corresponding in size to C9-L in
all samples for mAb 1C1 (Fig. 6a) and 12E7. No band
was detectable corresponding to the molecular size of
the predicted human C9-S isoform, although both anti-
bodies are able to detect C9-L and C9-S isoforms
expressed in HEK293 cells (Fig. 1) with comparable sen-
sitivity, implying that the 481 amino acid isoform (C9-L)
is the main and predominant protein isoform expressed
in the human CNS as in the mouse CNS. Importantly,
subsequent quantitative analysis of C9-L levels normal-
ized to total protein stains revealed a ~ 20% reduction of
C9-L levels in cases with C9orf72 repeat expansions
compared to controls (p = 0.001) (Fig. 6b). There were
no significant differences in C9orf72 protein levels
within each cohort between cases presenting clinically
Fig. 5 C9orf72 complex interacts with members of the RAB3 protein family. a Immunoblot analysis of HA-immunoprecipitated proteins from lysates of
HEK293 cells co-expressing HA-tagged human C9orf72 and HA-tagged SMCR8 with various FLAG-tagged Rabs showing co-immunoprecipitation of all
members of the RAB3 family with the C9orf72 complex. Other Rabs were used as positive (RAB8 subfamily, RAB39B) or negative (RAB1A, RAB7A,
RAB5A) controls based on published reports. b Immunoblot against RAB3 of control (IgG alone) or endogenous C9orf72 immunoprecipitated proteins
from lysates of adult mouse brain. MW size marker: PageRule Plus Prestained Protein Ladder (a and b). c Double-label immunofluorescence of 30 day
old human iPSC-derived motor neurons showing co-localization of C9orf72 (green) with RAB39B (red, upper panel) or RAB3 (red, lower panel) in a
subset of C9orf72-positive puncta. C9orf72 labeled with 12E7 in the upper panel and 1C1 in the lower panel. d Graph showing the percentage of
C9orf72 positive puncta co-localizing with RAB3 or RAB39B. Values are shown as mean ± SD
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with either ALS, FTD/ALS or FTD and there were no
associations between cerebellar C9orf72 protein levels
and disease duration, age at death or post-mortem delay.
Finally, to further analyze for potential biochemical al-
terations of C9orf72 in mutation carriers, proteins were
sequentially extracted from frozen frontal cortex from
cases with or without a C9orf72 repeat expansion, using
a series of buffers with an increasing ability to solubilize
proteins. C9-L was found to be present in the protein
fractions enriched for soluble proteins (low salt and Tri-
ton X-soluble fractions) but not in the fractions enriched
for insoluble proteins (sarkosyl and urea soluble frac-
tions). There were no changes in solubility between
C9orf72 mutation carriers and controls (Fig. 6c). Overall,
these results demonstrate that C9orf72 is a low abun-
dant, cytoplasmic soluble protein in the human CNS
with C9-L being expressed as the predominant protein
isoform and with reduced protein levels as consequence
of C9orf72 repeats expansions.
Discussion
An abnormal hexanucleotide expansion in a non-coding
region of C9orf72 is the most common genetic cause of
ALS and FTD [13, 40]. The mechanisms of how this
mutation contributes to neurodegeneration are unclear
with haploinsufficiency of C9orf72 functions suggested
as one potential disease mechanism based on consist-
ently observed reduced RNA transcript levels in tissues
of C9orf72 mutation carriers [13, 17, 52]. However, due
to little knowledge on C9orf72 expression, localization
and functions particularly in the CNS, further insights if
and how reduced C9orf72 proteins levels might contrib-
ute to disease pathogenesis are currently limited.
Here, we generated and characterized novel knock-out
validated C9orf72 monoclonal rat and mouse antibodies
that indicate that C9orf72 is predominantly, if not exclu-
sively, expressed as the long 481 amino acid isoform in
human and mouse tissues. Utilizing these antibodies we
detected reduced C9orf72 protein levels in the cerebel-
lum as consequence of C9orf72 repeat expansions in our
studied cohort of C9orf72 mutation carriers. Finally, we
identified C9orf72 to be localized to the presynapses and
able to interact with members of the RAB3 protein fam-
ily, suggestive of a role for C9orf72 in regulating SV
functions by potentially acting as GEF for RAB3. These
findings provide important novel insights into the
Fig. 6 Reduced C9orf72 expression levels in the cerebellum of C9orf72 mutation carriers. a Immunoblot analysis of C9orf72 protein levels in RIPA
lysates extracted from frozen cerebellar gray matter of C9orf72 mutation cases and neurologic controls reveals a single band ~ 50 kDa corresponding
in size to the long 481 amino acid isoform of C9orf72 (C9-L). Total protein stains are shown as loading controls. The blot shown is representative of
three independent experiments. b Quantification of C9orf72 protein levels in the cerebellum of n = 17 cases with C9orf72 repeat expansions (C9+) and
n = 26 controls (C9-). Dot blot of normalized C9orf72 values with mean and standard deviation shown as line and error bars. Different colors represent
clinical phenotypes (green = FTD; red = ALS/FTD; blue = ALS). p = 0.001 by Student’s two-tailed, unpaired t test. c Proteins were sequentially extracted
from frozen frontal cortex of C9orf72 mutation carriers (C9+) and controls (C9-) with a series of buffers of increasing stringency to receive low salt (LS),
high-salt Triton-X-100 (TX), sarkosyl (SARK), and urea protein fractions for immunoblot analysis. Human C9orf72 (C9-L) is present in all cases in the
fractions enriched for highly soluble proteins (LS and to lesser extent TX) with no changes observed in solubility between C9+ and C9- cases. MW size
marker: PageRule Plus Prestained Protein Ladder (a and c)
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physiological role of C9orf72 in the CNS, with signifi-
cant implications for future studies addressing the po-
tential contribution of haploinsufficiency in C9orf72
disease pathogenesis as well as therapeutic strategies.
Based on C9orf72 RNA transcripts two human and
three murine C9orf72 protein isoforms have been pre-
dicted. Previous biochemical studies of endogenous
C9orf72 protein expression have provided inconsistent re-
sults with reported presence of only C9-L [41, 53] or C9-L
and C9-S [56] as well as presence of only murine variant 1
[23, 38] or all three mouse variants [4]. This observed
variability is likely due to use of antibodies that lack suffi-
cient specificity as illustrated by our results of commer-
cially available C9orf72 antibodies on C9orf72 knock-out
mouse brain tissue (Additional file 1: Figure S2), a tech-
nical limitation also reported by others [42, 53]. Here, util-
izing knock-out validated C9orf72 mAbs generated
against epitopes that allow detection of all predicted iso-
forms in vitro, one band was observed in examined mouse
and human tissues corresponding in size to human C9-L
and the corresponding variant 1 of murine C9orf72. While
this does not exclude that additional C9orf72 protein iso-
forms might be present at amounts below detection limit
of our immunoblot assay, our data indicate that the long
481 amino acid isoform is by far the most predominantly
expressed C9orf72 protein isoform in mouse and human.
Biochemical analyses of C9-L extracted from human post-
mortem tissue revealed no changes in solubility of C9-L
between C9orf72 mutation carriers and controls, which is
consistent with a previous report [56]. However, we found
that C9-L is mostly a soluble protein with presence in LS
and TX fractions, in contrast to a previous study reporting
significant amount of C9orf72 in TX-insoluble, urea-soluble
protein fractions [56]. Discrepancies between both studies
might be explained by different antibody specificities and
differences in extraction methods.
Reduced C9-L levels in postmortem brain tissue of
C9orf72 mutation carriers have been reported for some cor-
tical regions but surprisingly not for cerebellum [41, 53, 56],
the region with highest C9orf72 RNA expression [40] and
consistently reported reduced transcript levels in C9orf72
mutation carriers [17, 52, 53]. However, the overall inter-
pretation of these data in providing evidence for haploinsuf-
ficiency on the protein level has been complicated by
non-specific binding of antibodies, insufficient statistical
power due to small sample size and the risk that reduced
protein levels observed in cortical regions might be influ-
enced by neurodegenerative changes instead of C9orf72 mu-
tation specific consequences. This latter limitation is
underpinned by our finding of a strong negative correlation
between presence of neurodegeneration/cell death and
C9orf72 levels in cortical regions. Therefore, we focused for
our quantitative immunoblot analysis on the cerebellum, a
region without overt neurodegeneration in ALS and FTD.
Utilizing our novel knock-out validated mAbs we found
cerebellar C9-L protein levels reduced to ~ 80% in our co-
hort of C9orf72 mutation carriers (n= 17) compared to con-
trols (n = 26). Notably, the observed degree of protein
reduction is in good agreement with the reported decrease
to 70% for RNA transcripts encoding for the long isoform in
C9orf72 mutation carriers [13, 52]. No associations between
clinical phenotypes (ALS, ALS/FTD or FTD), age at onset
and disease duration with cerebellar C9orf72 protein levels
were seen. This is consistent with the reported lack of asso-
ciations between cerebellar transcript levels and clinical fea-
tures [52]; however, the number of cases per clinical
subgroup in our cohort might have been too small to detect
subtle associations with protein levels and this should be
further addressed in larger cohorts.
While our data expand the evidence for reduced protein
expression as a consequence of C9orf72 hexanucleotide
expansions, it remains to be established if and how re-
duced proteins levels might contribute to disease patho-
genesis. The fact that reduced protein levels are described
in unaffected and affected brain regions in C9orf72 muta-
tion carriers, implies that reduced C9orf72 levels are not
causing neurodegeneration per se, an interpretation fur-
ther supported by the absence of obvious neurological
phenotypes in C9orf72 knock-out mice [3, 23, 38, 47].
However, these data would be in line with a scenario that
different cells and/or neuronal subpopulations might have
distinct vulnerabilities in tolerating reduced C9orf72 levels
which might trigger neurodegeneration in combination
with additional stressors [45], and/or as consequence of a
cooperative gain- and loss-of-function mechanism of re-
peat expansions as recently proposed [46].
One crucial prerequisite to further address the poten-
tial role of reduced C9orf72 levels in disease pathogen-
esis is to gain further insights on its physiological
function in the CNS. Several recent studies have demon-
strated that C9orf72 interacts with the SMCR8 protein
and regulates the endo-lysosomal and autophagy path-
ways [1, 21, 45, 48, 51, 54, 57]. Our immunofluorescence
data of human iPSC derived human motor neurons are
consistent with these studies by demonstrating endogen-
ous co-localization of almost all C9orf72-immunoreactive
vesicles with SMCR8 and co-localization of ~ 40% of
C9orf72-positive vesicles with the lysosomal marker
LAMP2. Most excitingly, our complementary histological
and biochemical approaches provided strong evidence for
an additional role of C9orf72 at presynaptic terminals by
acting as putative GEF for members of the RAB3 protein
family. Immunohistochemically, we found a predomin-
antly presynaptic staining pattern of C9orf72 in mouse
brains most prominently in the synapse-rich hippocampal
mossy fiber system, where it co-localized with SV marker
proteins. No immunoreactivity was observed in glial cells
in mouse tissue in agreement with our in situ hybridization
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data and with the predominant neuronal expression of
C9orf72 reported in transgenic mice with targeted LacZ in-
sertion into the C9orf72 locus [49] under physiological
conditions. However, in future studies it will be interesting
to investigate whether cellular expression patterns might
change under neuroinflammatory and neurodegenerative
conditions. In accordance with our immunohistochemical
findings, C9orf72 was present in biochemical preparations
of synaptosomes and particularly in fractions enriched for
soluble cytosolic contents of synaptic vesicles, which is
suggestive for a protein able to reversibly and transiently
interact with SVs [22]. This interpretation is further
supported by the co-localization of C9orf72 in a sub-
set of synaptophysin-positive vesicles in human iPSC
derived motor neurons. Like all other trafficking steps
in eukaryotes, SV cycle and presynaptic neurotrans-
mitter release is governed by specific Rabs [6] with
the most abundant Rabs in neurons represented by
homologues of the RAB3 protein family specifically
localizing to SVs and with well studied roles in regu-
lating/modulating neurotransmitter release [43, 44].
Our findings of an interaction of C9orf72 with RAB3
family members by co-immunoprecipitation experi-
ments and double-label immunofluorescence indicate
that C9orf72 might act as GEF for RAB3 thereby
modulating the SV cycle. In support of this interpret-
ation, it is noteworthy that subtle cognitive and im-
aging alterations observed in a recent study of
presymptomatic C9orf72 mutation carriers were pro-
posed to represent an early and non-evolving pheno-
type related to neurodevelopmental effects of C9orf72
mutation [5]. However, the exact role of C9orf72 as
potential GEF in modulating neurotransmission and
other steps of the SV cycle which also includes Rabs
involved in endosomal and autophagosomal functions
[6] will require further functional investigation.
One limitation of our study is that the subcellular distri-
bution of C9orf72 in postmortem human brain tissues
could not be investigated immunohistochemically due to
the lack of immunoreactivity in human FFPE tissue using
the knock-out validated protocol successfully established
in mouse FFPE tissue. This might be potentially explained
by protein degradation due to postmortem delay. How-
ever, we observed no association between C9orf72 levels
and postmortem delay and mouse tissue with different
PM delay mimics in our biochemical analysis. An add-
itional and perhaps more likely explanation seems to be
related to formalin fixation times. For mouse tissue we ob-
served decreasing immunoreactivity signals for formalin
fixation times > 24 h, while the available human postmor-
tem tissue was routinely fixed for several weeks up to
month. This issue needs to be addressed in future studies
using differently processed autopsy and perhaps biopsy
tissues if available.
Conclusions
In summary, our data provide evidence for haploinsuffi-
ciency at the protein level in C9orf72 mutation carriers
and novel insights into the physiological role of C9orf72
at the presynapse with a potential role as GEF for RAB3
involved in SV exocytosis. These findings have signifi-
cant implications for future studies aimed at addressing
C9orf72 pathogenesis as well as therapeutic strategies.
Furthermore, these novel mAbs against C9orf72 will be
useful tools to further dissect the cellular and molecular
functions of C9orf72.
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